Secreted frizzled related protein 1 (SFRP1) is an antagonist of the transmembrane frizzled receptor, a component of the Wnt signaling pathway, and has been suggested to be a candidate tumor suppressor in several human malignancies. Since SFRP1 is located at chromosome 8p11, where lung cancers also exhibit frequent allelic loss, we hypothesized that the inactivation of SFRP1 is also involved in lung carcinogenesis. To substantiate this, we performed mutational analysis of SFRP1 for 29 nonsmall-cell lung cancer (NSCLC) and 25 small-cell lung cancer (SCLC) cell lines, and expression analysis for the same cell lines. Although somatic mutations were not detected in the coding sequence, downregulation of SFRP1 was observed in 14 (48%) NSCLC and nine (36%) SCLC cell lines. We analysed epigenetic alteration of the SFRP1 promoter region and detected hypermethylation in 15 (52%) of 29 NSCLC cell lines, two (8%) of 25 SCLC cell lines, and 44 (55%) of 80 primary lung tumors. By comparing the methylation status with SFRP1 expression, we found a significant correlation between them. We also performed loss of heterozygosity (LOH) analysis and found that 15 (38%) of 40 informative surgical specimens had LOH in the SFRP1 gene locus. Furthermore, we performed colony formation assay of two NSCLC cell lines (NCI-H460 and NCI-H2009) and found the reduction of colony formation with SFRP1 transfection. In addition, we also detected that SFRP1 inhibits the transcriptional activity of b-catenin, which is thought to be a downstream molecule of SFRP1, with luciferase reporter assay. Our current studies demonstrated that the SFRP1 gene is frequently downregulated by promoter hypermethylation and suppresses tumor growth activity of lung cancer cells, which suggests that SFRP1 is a candidate tumor suppressor gene for lung cancer.
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, 13q14 for RB, and multiple loci of 3p for FHIT, RASSF1A, and/or other unidentified genes (Sekido et al., 2002 Mori et al., 2004; Ito et al., 2005) . In addition, LKB1/STK11 located at 19p has also been identified as a candidate TSG in lung cancer (Sanchez-Cespedes et al., 2002) . Meanwhile, there are still other chromosomal regions where the target genes are not fully identified such as 1p and 8p. Chromosome 8p is interesting since loss of 8p is one of the most common findings in cytogenetic and LOH analyses, and a frequent and early event in the pathogenesis of lung cancer (Wistuba et al., 1999; Girard et al., 2000; Pei et al., 2001; Minna et al., 2002) . Furthermore, allelic loss of chromosome 8p is frequently detected in a variety of solid tumors and hematological malignancies with allelotyping studies (Emi et al., 1992) . These findings strongly suggest the presence of candidate TSGs in this region. In fact, candidate TSGs such as FEZ1/LZTS1 (FEZ1) and DLC1, located at chromosome 8p21-22, have been recently identified in lung cancer (Toyooka et al., 2002; Yuan et al., 2004) . To detect TSGs located at 8p, we performed PCR assay to screen homozygous deletions, which could be a hallmark indicating the existence of TSG (Girard et al., 2000) . Although we searched for homozygous deletions in the region of 8p11-8p23, including the secreted frizzled related protein 1 (SFRP1) locus at 8p11.21 with intervals of approximately 1-mega base pairs using 38 PCR primer sets, no homozygous deletion was found in 124 cancer cell lines (data not shown).
Alterations of the genes encoding components in the Wnt signaling pathway have been recognized as a common event in the development and/or progression of several human cancers (Polakis, 2000; Giles et al., 2003; Morin and Weeraratna, 2003; Howe and Brown, 2004) . However, the prevalence and pathogenetic significance of the alterations in the Wnt signaling pathway is not well known in human lung cancer. Although alterations of APC and CTNNB1 (b-catenin) were shown to be infrequent, the constitutive activation of the Wnt signaling pathway caused by a CTNNB1 mutation was shown to be involved in the development of a subset of human lung cancer (Horii et al., 1992; Shigemitsu et al., 2001; Sunaga et al., 2001) . Meanwhile, the SFRP family genes are antagonists of the transmembrane frizzled receptor, which prevent the Wnt signaling by competing with Wnt ligands. Among the SFRP family, the SFRP1 gene, which is located at 8p11, has been shown to be downregulated in colorectal, breast, bladder, and ovarian carcinomas, along with malignant mesothelioma, and has been suggested to be a strong candidate TSG (Caldwell et al., 2004; Klopocki et al., 2004; Lee et al., 2004; Stoehr et al., 2004; Suzuki et al., 2004; Takada et al., 2004) . As SFRP1 is located at 8p11.2, within the frequent deletion region of lung cancer, we hypothesized that SFRP1 might be the target TSG for lung cancer as well.
First, to determine whether primary lung cancer show allelic loss of SFRP1 locus, we performed LOH analysis with the D8S1180 microsatellite marker, which is located only 6 kbp upstream from the SFRP1 gene. Laser capture microdissection (LCM) was performed as described previously using a PixCell laser capture microscope (Arcturus Engineering, Mountain View, CA, USA) (Uchiyama et al., 2003) . LOH was considered present if the reduction rate of the height of the allele in the tumor was more than 40%, as previously defined (Uchiyama et al., 2003) . Genomic DNA extracted from noncancerous lung tissues served as the normal control. Among the 40 informative cases of 80 primary lung cancer specimens tested, 15 (38%) samples showed allelic loss of D8S1180, and 25 (62%) samples showed heterozygosity (data not shown).
Next, we performed sequencing analysis using genomic DNAs extracted from 29 NSCLC and 25 SCLC cell lines with four primer sets to cover the entire coding region of exons 1-3 to determine whether or not the SFRP1 gene is genetically altered in lung cancer. We detected a common polymorphism in 18 NSCLC (62%) and 11 SCLC (44%) cell lines, which is an in-frame three-base (GCA) deletion after nucleotide 37, but found neither homozygous deletion nor mutation (data not shown). The polymorphism has no correlation with SFRP1 gene expression level, and its methylation status as shown below (Table 1) .
To determine whether SFRP1 gene expression was downregulated in lung cancers, we performed quantitative real-time PCR analysis for 29 NSCLC and 25 SCLC cell lines. SFRP1 was downregulated by more than 100-fold in 14 (48%) NSCLC and nine (38%) SCLC cell lines compared with normal lung tissue (Table 1, Figure 1 ). The frequency of lung cancers with SFRP1 downregulation seems to be similar to that in several kinds of malignancy such as bladder cancers (38%) (Stoehr et al., 2004) , breast cancers (46%) , and malignant mesotheliomas (48%) (Lee et al., 2004) , but lower than in colorectal cancers (76%) (Caldwell et al., 2004) .
To determine whether downregulation of the SFRP1 gene is due to its promoter hypermethylation, we performed methylation-specific PCR (MSP), and representative cases were confirmed by bisulfite sequencing analysis (Figure 2a, b) . We found the promoter hypermethylation of SFRP1 in 15 (52%) of 29 NSCLC cell lines and two (8%) of 25 SCLC cell lines (Table 1) . Promoter hypermethylation is significantly more frequent in NSCLC than SCLC (Po0.001). There was a significant correlation between the methylation status Figure 1a) . Furthermore, 44 (55%) of 80 primary NSCLCs also showed hypermethylation, but no correlation was found from comparing the methylation status with the clinical factors (data not shown). We also treated NCI-H460 (large-cell carcinoma) cells with 1 mM 5-aza-2 0 -deoxycytidine (5-aza-dC) to determine whether DNA demethylation treatment can induce reactivation of SFRP1 expression. After the treatment, the expression of SFRP1 was screened in both treated and untreated cell lines by RT-PCR. SFRP1 was restored in the treated NCI-H460 cells (Figure 2c ).
Since these results suggested that SFRP1 is also a strong candidate TSG for lung cancer, we performed a colony formation assay to test the growth-inhibitory effect of exogenously expressed SFRP1. After transfection of the plasmid of SFRP1 (pSFRP1-V5) into the NCI-H460 and NCI-H2009 (adenocarcinoma) cells, we selected transfected cells with G418 treatment, and counted the surviving colonies. SFRP1 showed suppression of colony formation in both the NCI-H460 (7076.6%) and NCI-H2009 (47715%) cells, indicating that SFRP1 has growth-suppressive activity in lung cancer cells (Figure 3a, b) . Although SFRP1 was shown to have tumor growth-suppressive activity by induction of apoptosis in colorectal cancer , no clear difference in the number of apoptotic cells was observed between transfected and control cells with Annexin V staining, which may suggest that SFRP1 has less effect on apoptosis in lung cancer cells than in colorectal cancer cells (data not shown).
Since SFRP1 has been shown to inhibit Wnt transcriptional activity in colorectal cancer, we hypothesized that SFRP1 might also inhibit Wnt transcriptional activity in lung cancer cells. To confirm this possibility, we performed luciferase reporter assay in NCI-H460 cells. When transfected with wild-type or activated type of Ser37Cys mutant b-catenin, relative T-cell factor (TCF) activity was stimulated three-to 15-fold compared with the empty vector controls, respectively (Figure 3c ). When SFRP1 was cotransfected, SFRP1 inhibited the relative TCF activity of both wild-type and Figure 1 SFRP1 expression of lung cancer cell lines. Quantitative real-time PCR was performed by TaqMan Gene Expression Assays in this study (Applied Biosystems, Foster City, CA, USA). First-strand cDNA was generated from 5 mg of total RNA using Superscript II (Invitrogen, New York, NY, USA) and random primers (Takara Bio, Otsu, Japan) as previously described . All real-time PCR assays were carried out in MicroAmp optical 96-well reaction plates on an ABI PRISM 7900 Sequence Detector System (Applied Biosystems) according to the manufacturer's instructions. The relative RNA expression levels were calculated via a modified comparative C T method. A standard curve for each gene was established to obtain PCR amplification efficiency. A mathematical model was applied to determine expression levels of the target gene in individual samples, relative to a reference gene and a calibrator sample, using the following formula: ðE target Þ DC T targetðcalibratorÀsampleÞ = ðE reference Þ DC T referenceðcalibratorÀsampleÞ , where E target is PCR efficiency of the target gene transcript and E reference is PCR efficiency of reference gene transcript. The reference gene used in this study was the b-actin (Suzuki et al., 2002) . Primer sequences used in this study included: SFRP1-um-S, 5 0 -AGTGT TGTGTGTTTGTTGTTTTGT-3 0 , and SFRP1-um-AS, 5 0 -TCCA CAACATCAAAACTACCTCCA-3 0 , for unmethylated sequence, and SFRP1-m-S, 5 0 -AGTGTCGCGCGTTCGTCGTTTCGC-3 0 , and SFRP1-m-AS, 5 0 -TCCGCGACGTCGAAACTACCTCCG-3 0 , for methylated sequence. Methylated bands were detected in H2009, H460, and HCC44, while unmethylated bands were detected in H1666, H157, H1184, and normal lung tissue. (c) Restoration of the SFRP1 gene expression in NCI-H460 cells by 1 mM 5-aza-dC treatment for 72 and 120 h SFRP1 silencing in non-small-cell lung cancer T Fukui et al mutant b-catenin. The same trend was also observed in NCI-H2009 cells (data not shown). However, the association between the inhibition of Wnt pathway and growth suppression of lung cancer cells shown above remains unclear, although similar inhibitory effects of SFRP1 against Wnt transcriptional activity on tumor cell growth were previously reported in colorectal cancer cell lines .
In summary, we demonstrated that the transcription of SFRP1 is frequently silenced in human lung cancer, that SFRP1 promoter is frequently methylated, and has a significant association with SFRP1 downregulation. We also demonstrated that SFRP1 suppresses tumor growth in vitro, and that SFRP1 inhibits the transcriptional activity by b-catenin in canonical Wnt signaling pathway. These data suggest that SFRP1 could be one of the candidate TSGs on chromosome 8p in human lung cancer.
